BioCentury
ARTICLE | Company News

Five Prime cuts headcount by 20%

January 18, 2019 7:00 PM UTC

Five Prime Therapeutics Inc. (NASDAQ:FPRX) said it will reduce headcount by 41 (20%). Cuts will come from research, pathology and manufacturing.

The cancer company’s pipeline includes five programs. Its lead compound, bemarituzumab, is in Phase III to treat gastric cancer...

BCIQ Company Profiles

Five Prime Therapeutics Inc.